DMAC - NASDAQ

DiaMedica Therapeutics Inc.

DMAC·NASDAQ

$5.84

+1.2%

HealthcareBiotechnology

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$314.68M

EPS-0.7000

P/E Ratio-8.34

Earnings Date08/11/2026

dmac

Shares Outstanding

Last Annual Value

46.98M

3-Year CAGR

21%

5-Year CAGR

25%

10-Year CAGR

29%

Adjust for Inflation

DiaMedica Therapeutics Inc. Competitors Analysis of shares-outstanding

DMAC · NASDAQ

Company	shares-outstanding	CAGR 3Y	CAGR 5Y	CAGR 10Y
DiaMedica Therapeutics Inc. NASDAQ:DMAC	46.98M	13.0%	17.7%	25.8%
I-Mab NASDAQ:IMAB	81.19M	-0.8%	1.3%	N/A
Aardvark Therapeutics, Inc. Common Stock NASDAQ:AARD	19.62M	15.0%	N/A	N/A
Candel Therapeutics, Inc. NASDAQ:CADL	52.96M	22.3%	13.0%	N/A
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ:CTNM	27.70M	3.1%	2.0%	N/A
LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX	25.30M	92.6%	N/A	N/A
Humacyte, Inc. NASDAQ:HUMA	158.16M	15.2%	31.7%	N/A
Replimune Group, Inc. NASDAQ:REPL	80.56M	11.4%	11.7%	N/A
Galectin Therapeutics Inc. NASDAQ:GALT	63.90M	2.0%	1.8%	8.1%
Annexon, Inc. NASDAQ:ANNX	155.11M	27.0%	32.3%	N/A
Genelux Corporation NASDAQ:GNLX	37.18M	15.0%	9.5%	N/A

DiaMedica Therapeutics Inc. Fair Value Envelope

DMAC · NASDAQ

Our analysis suggests that DMAC has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.84, this represents a potential HIDDEN relative to our calculated worth for DiaMedica Therapeutics Inc..

HIDDEN

Intrinsic Value

Current Price: $5.84

Related Guides

Blog Categories

Continue your DMAC research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.